Today, 2024, June 4, the Legislative Yuan passed the Regenerative Medicine Act and Regenerative Pharmaceuticals act with a third and final reading, ushering a new era of regenerative medicine. Xenogeneic cell therapy is included and regulated in both acts. As a leader and pioneer in xenogeneic cell cancer immunotherapy, eXCEL is dedicated to bringing our transformative cellular medicine to the clinics to ameliorate the lives of cancer patients.